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ABSTRACT
Bacterial b-glucuronidases expressed by the symbiotic in-
testinal microbiota appear to play important roles in drug-
induced epithelial cell toxicity in the gastrointestinal (GI) tract.
For the anticancer drug CPT-11 (irinotecan) and the nonsteroidal
anti-inflammatory drug diclofenac, it has been shown that
removal of the glucuronide moieties from drug metabolites by
bacterial b-glucuronidases in the GI lumen can significantly
damage the intestinal epithelium. Furthermore, selective disrup-
tion of bacterial b-glucuronidases by small molecule inhibitors
alleviates these side effects, which, for CPT-11 {7-ethyl-10-[4-
(1-piperidino)-1-piperidino]}, can be dose limiting. Here we
characterize novel microbial b-glucuronidase inhibitors that
inhibit Escherichia coli b-glucuronidase in vitro with Ki values
between 180 nM and 2 mM, and disrupt the enzyme in E. coli
cells, with EC50 values as low as 300 nM. All compounds
are selective for E. coli b-glucuronidase without inhibi-
ting purified mammalian b-glucuronidase, and they do not
impact the survival of either bacterial or mammalian cells. The
2.8 Å resolution crystal structure of one inhibitor bound to
E. coli b-glucuronidase demonstrates that it contacts and
orders only a portion of the “bacterial loop” present in
microbial, but not mammalian, b-glucuronidases. The most
potent compound examined in this group was found to
protect mice against CPT-11–induced diarrhea. Taken to-
gether, these data advance our understanding of the chemical
and structural basis of selective microbial b-glucuronidase




is employed worldwide for the treatment of a variety of
solid malignancies, but its efficacy is often limited by severe
gastrointestinal (GI) toxicity (Rothenberg et al., 1996; Rougier
et al., 1997, 1998; Cunningham et al., 1998; Saltz et al., 2000;
Fuchs et al., 2003; Hu et al., 2006; Kurita et al., 2011). CPT-11
is most frequently used in first- and second-line treatment of
metastatic colon cancers, typically in combination with other
agents (Smith et al., 2006; Kambe et al., 2012). More recently,
CPT-11 has been employed in preclinical and clinical trials
against a range of other neoplasticities, including brain tu-
mors, lung, breast, gastric, pancreatic, and gynecologic cancers
(Matsumura et al., 2010; Han et al., 2012; Jo et al., 2012; Kim
et al., 2012; Spigel et al., 2012; Zaniboni et al., 2012; Lee et al.,
2013).
CPT-11 is a prodrug that is converted to SN-38 (7-ethyl-10-
hydroxy-camptothecin) by carboxylesterase enzymes. SN-38,
the active metabolite of CPT-11, induces antitumor effects by
poisoning the human topoisomerase I catalytic cycle, leading
to cell death (Kawato et al., 1991; Mathijssen et al., 2001; Ma
and McLeod, 2003). The fate of SN-38 in vivo is further
regulated by UDP-glucuronosyltransferase (UGT) enzymes in
the liver and other tissues. UGT isoforms, in particular
UGT1A1, catalyze the conjugation of a glucuronide group onto
SN-38, producing the inactive compound SN-38 glucuronide
(SN-38G), which is marked for elimination through the bile
and into the GI tract (Nagar and Blanchard, 2006). However,
as SN-38G passes through the GI tract, it acts as a substrate
for bacterial b-glucuronidases present in intestinal symbiotic
microbes (Tobin et al., 2003; Stein et al., 2010). These enzymes,
in turn, reactivate SN-38 in situ, resulting in toxic injury to
the intestinal epithelial cells (Araki et al., 1993). Indeed, the
severity of CPT-11–induced diarrhea is correlated with levels
of b-glucuronidase activity in the intestinal lumen, and the
intestinal microbiota have been found to play an important
role in the development of this toxicity (Takasuna et al., 1996,
1998; Mathijssen et al., 2001; Brandi et al., 2006). Although
most early-onset diarrhea associated with CPT-11 treatment
can be treated with antimotility agents, the delayed GI toxicity
associatedwith SN-38 can be refractory to standard treatments
(Saliba et al., 1998). It has now been convincingly demonstrated
that the intestinal toxicity of CPT-11 limits dose intensifi-
cation and optimized delivery of CPT-11 (Abigerges et al., 1994;
Ducreux et al., 2003; Zhao et al., 2004).
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ABBREVIATIONS: CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]; DMSO, dimethyl sulfoxide; GI, gastrointestinal; LB, lysogeny broth; PNPG,
p-nitrophenyl b-D-glucuronide; SN-38, 7-ethyl-10-hydroxycamptothecin; SN-38G, SN-38 glucuronide; UGT, UDP-glucuronosyltransferase.
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The role microbial enzymes expressed by symbiotic bacteria
plays in therapeutic metabolism has been appreciated since
the early days of drug discovery (Sousa et al., 2008). We
recently hypothesized that selective microbial b-glucuronidase
inhibitors would alleviate CPT-11–induced toxicity. In vitro
and cell-based assays demonstrated that a set of chemically
similar compounds identified by high-throughput screening
displayed potent inhibition of Escherichia coli b-glucuronidase
and did not impact the viability of cultured bacterial or
mammalian cells (Wallace et al., 2010). Crystal structures of
inhibitors in complex with E. coli b-glucuronidase reveal
that the small molecules bind to a loop present in bacterial
b-glucuronidases but missing in the mammalian orthologs;
accordingly, the inhibitors examined had no inhibitory effect
in vitro on a mammalian b-glucuronidase (Wallace et al.,
2010). Oral administration of one of the inhibitors to mice
alleviated CPT-11–induced diarrhea and intestinal damage
(Wallace et al., 2010). Furthermore, in a subsequent study,
the administration of the same inhibitor protected mice
from small intestinal ulceration caused by the nonsteroidal
anti-inflammatory drug diclofenac, which is also subject to
glucuronidation and reactivation in the intestinal lumen
(LoGuidice et al., 2012).
Here we describe the inhibitory profile of four novel in-
hibitors that are chemically distinct from the originally
reported set (Wallace et al., 2010; Ahmad et al., 2011). These
compounds are shown to be in vitro inhibitors of E. coli
b-glucuronidase but are nonlethal to cultured E. coli and
mammalian cells. The X-ray crystal structure of E. coli
b-glucuronidase in complex with one of the inhibitors reveals
that it binds to the entrance of the enzyme’s active site and
makes contact with, but does not completely order, the flexible
bacterial loop unique to the microbial b-glucuronidases. We
also show that the most potent of these new compounds
protects mice from CPT-11–induced diarrhea. Taken to-
gether, these data enhance our understanding of the selective
modulation of microbial b-glucuronidases, which may lead to
the targeted alleviation of drug-induced toxicity in the human
GI tract.
Materials and Methods
Expression and Purification of E. coli b-Glucuronidase. E. coli
b-glucuronidase (EC 3.2.1.31) was expressed and purified as described
previously (Wallace et al., 2010). Purified E. coli b-glucuronidase was
stored in 20 mM HEPES, 50 mM NaCl, pH 7.4 at ∼10 mg/ml at280°C.
The D360–376 form of E. coli b-glucuronidase was created using
polymerase chain reaction mutagenesis, confirmed by sequencing and
purified as described previously (Wallace et al., 2010).
Inhibitor Compounds. Compounds (Fig. 1) identified from high-
throughput screening (Wallace et al., 2010; Ahmad et al., 2011) were
purchased from ASINEX, Inc. (Moscow, Russia). Each compound was
provided as a solid powder and dissolved initially in 100% dimethyl
sulfoxide (DMSO) at 25 mM.
Kinetic and Equilibrium Inhibition Assays. Inhibition assays
were conducted by measuring the b-glucuronidase-catalyzed conver-
sion of p-nitrophenyl b-D-glucuronide (PNPG) to p-nitrophenol. PNPG
was acquired from Sigma-Aldrich (St. Louis, MO), and stored by
dissolving in water at 250 mM. The conversion of increasing
concentrations of PNPG to p-nitrophenol in the presence of 10 nM
enzyme was measured in the presence of increasing concentrations of
our putative inhibitors; zero-substrate and zero-inhibitor controls
were carried out at the same time. Reactions were conducted in 96-
well, clear-bottom assay plates (Costar, Tewksbury, MA) at 37°C in 50
ml of total volume. The reaction consisted of 10 ml of assay buffer (5%
DMSO and 500 mM HEPES, pH 7.4), 5 ml of inhibitor solution
(various concentrations), 5 ml of 100 nM enzyme, and 30 ml of
substrate (various concentrations). Product formation was calculated
by measuring the change in absorbance over time at 410 nm using
a PHERAstar Plus microplate reader (BMG Labtech, Ortenberg,
Germany). The acquired data were analyzed using Microsoft Excel
(Microsoft, Redmond, WA) and SigmaPlot 11.0 (Systat Software, San
Jose, CA). From these data, Ki values were calculated for each of the
inhibitors.
A related assay was employed to calculate the IC50 values in the
following manner. An analogous 50 ml reaction, consisting of enzyme
(1 nM final), buffer, PNPG (1 mM final), and variable concentrations
of the inhibitors, was incubated at 37°C for 6 hours to allow the
reaction to reach equilibrium and then quenched with 100 ml 0.2 M
sodium carbonate. The percent inhibition for each concentration of
inhibitor was calculated based on changes in absorbance and used to
plot a dose-response curve. The IC50 value was calculated as the
concentration of inhibitor that produced 50% in vitro inhibition. The
Fig. 1. Chemical structures of the Inhibitors 1–8.
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same assay was performed with purified bovine liver b-glucuronidase
with PNPG as the substrate.
We also tested the ability of these compounds to inhibit b-glucuronidase
in E. coli cells. We grew chemically competent E. coli cells, trans-
formed with the pET-28a vector containing the b-glucuronidase
gene, to an optical density (OD)600 of 0.6 in lysogeny broth (LB)
medium and used a small aliquot in an assay similar to the in vitro
IC50 assay described above. The cells (39 ml) were incubated with 1 ml
of variable concentrations of inhibitor and 10 ml of 1 mM PNPG at
37°C for 6 hours. The reaction was quenched with 100 ml 0.2 M
sodium carbonate. The amount of substrate turnover and therefore
the amount of inhibition is calculated from the change in absorbance
compared with zero-inhibitor controls. EC50 values were calculated
as the amount of inhibitor necessary to produce 50% inhibition. The
in vitro and cell-based assays employed here were similar to those
reported previously (Wallace et al., 2010).
Additional Glycosidase Enzymes. Mammalian (bovine liver) b-
glucuronidase (lyophilized powder, EC 3.2.1.31), Prunis dulcis
b-glucosidase (lyophilized powder, EC 3.2.1.21), Helix pomatia b-
mannosidase (ammonium sulfate suspension, EC 3.2.1.25), E. coli
b-galactosidase (lyophilized powder, EC 3.2.1.23), and bovine liver
b-galactosidase (lyophilized powder, EC 3.2.1.23) were purchased from
Sigma-Aldrich. The assays were conducted as previously published,
using the appropriate p-nitrophenyl-glycosidase compound as the
primary substrate for enzyme activity detection (Graef et al., 1977).
Each of the four inhibitors was tested for an effect on each glycosidase
enzyme activity by adding a concentration range of 0 to 100 mM to the
reaction mixture. The reaction was allowed to proceed for 6 hours at
37°C and then quenched with 100 ml 0.2 M sodium carbonate.
Absorbance was measured at the appropriate wavelength, and the
data were analyzed using Microsoft Excel and SigmaPlot 11.0.
Toxicity of Inhibitors toward Cultured Cells. The toxicity of
inhibitors to bacterial cells was examined by incubating chemically
competent E. coli cells, transformed with the pET-28a vector con-
taining the b-glucuronidase gene, and grown to an OD600 of 0.6 in LB
medium with each compound, as well as DMSO and ampicillin as
controls, for 6 hours. Cell survivability was measured by plating a
1025 dilution of the cells on LBmedia enriched with kanamycin. After
overnight incubation, colonies were counted to quantify cell viability.
We used a similar assay to assess each inhibitor’s toxicity toward
cultured HCT116 human colon cancer cells, which were grown and
cultured in Dulbecco’s modified Eagle’s medium. Aliquots of HCT116
cells were incubated with 100 mM of each lead for 24 hours. The
resulting viability of the cells was quantified by using the
CellQuanti-Blue Cell Viability Assay Kit (BioAssay Systems, Hayward,
CA). Cells were incubated with CellQuanti-Blue Reagent, and fluores-
cence was measured.
TABLE 1
In vitro and cell-based assays for b-glucuronidase activity and inhibitor
efficacy
Errors represent standard error, where n = 3.
E. coli b-Glucuronidase In Vitro E. coli CellBased
Ki IC50 EC50
nM
Inhibitor 5 217 6 42.6 542 6 93.7 306 6 8.35
Inhibitor 6 668 6 28.8 8890 6 2930 747 6 167
Inhibitor 7 1920 6 21.0 14,900 6 2530 NI
Inhibitor 8 957 6 22.8 6430 6 1380 1200 6 256
NI, no inhibition.
Fig. 2. Impact of increasing concentrations of Inhibitors 5–8 on the activity of bovine b-glucuronidase.
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Crystal Structure Determination. Crystals of E. coli b-glucu-
ronidase were obtained at 2 mg/ml protein with 30-fold molar excess
Inhibitor 8 (Fig. 1) in 17% polyethylene glycol 3350 (w/v), 250 mM
magnesium acetate, and 0.02% sodium azide (w/v) at 16°C. Crystals
first appeared after 5 days and were immediately cryoprotected with
perfluoropolyether vacuum pump oil (Sigma-Aldrich) and flash-cooled
in liquid nitrogen. Diffraction data were collected on the 22-BM beam
line at SER-CAT (Advanced Photon Source, Argonne National
Laboratory, Lemont, IL). Data in space group C2 were indexed and
scaled using HKL2000 (Otwinowski and Minor, 1997) to 2.83 Å re-
solution. The asymmetric unit contained two monomers. The struc-
ture was determined with Phaser as part of the software suite
PHENIX (PHENIX Project, Berkeley, CA) (McCoy et al., 2007) using
molecular replacement with the recent apo E. coli b-glucuronidase
structure (PDB ID 3K46) as a searchmodel. The structure was refined
using simulated annealing and torsion angle refinement with the
maximum likelihood function target in the program central nervous
system (crystallography and NMR system) and monitored using both
the crystallographic R and cross-validating R-free statistics (Brünger,
1997). The software suite PHENIX (PHENIX Project) (Adams et al.,
2002) was also employed for grouped B factor (with two groups: main
chain and side chain) and translation, libration, screw refinement.
The model was manually adjusted using Coot (Emsley and Cowtan,
2004) and 2Fo–Fc and Fo–Fc electron density maps. The ligand model
and definition files were generated using PRODRG (GlycoBioChem,
Dundee, Scotland, UK) (Schüttelkopf and van Aalten, 2004), and were
placed into electron density in the active site of both monomers in the
asymmetric unit.
Animal Studies. Animal experiments were performed according
to the Institutional Animal Care and Use guidelines approved by the
Institutional Animal Care and Use Committee (IACUC # 20070715
and 20100711) of the Albert Einstein College of Medicine, Bronx,
NY. CPT-11 was purchased from LC Laboratories (catalog num-
ber: I-4122; Woburn, MA), as a hydrochloride salt (.99% high-
performance liquid chromatography purified grade). CPT-11 (20 mg/ml)
and Inhibitor 5 (100 mg/ml) were dissolved in 0.25% (w/v) carbo-
xymethylcellulose sodium salt (Sigma-Aldrich; C5013) to make
stock solutions. As a vehicle control, all animals received an equiv-
alent volume (compared with experimental groups) of 0.25% (w/v)
carboxymethylcellulose sodium salt solution. BALB/cJ mice female
Fig. 3. Impact of Inhibitors 5–8 at 100 mM on the survival of E. coli (A) and HCT116 cells (B). Ampicillin and 10% Triton-X100 are used as positive
controls for microbial and human cell lethality, respectively. Additionally, 2% DMSO, in which the inhibitors are solubilized, is also shown. DMEM,
Dulbecco’s modified Eagle’s medium.
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(8–10 weeks old) were obtained from the Jackson Laboratories (Bar
Harbor, ME). The mice were housed in conventional metabolic cages
(N 5 1/cage) and kept in a room under controlled temperature
(20–22°C) and 12-hour day-night cycle. Animals had free access to
water and conventional food without fortification. Mice were divided
into four groups of 9 animals each: group 1, vehicle controls received
equivalent volume of 0.25% (w/v) carboxymethylcellulose sodium salt
solution intraperitoneally and by oral gavage (∼100 ml twice per day);
group 2, Inhibitor 5 gavaged (10 mg/d) twice per day (every 10 hours)
starting on day21with oral gavage of 0.25% (w/v) carboxymethylcellulose
sodium salt solution and intraperitoneally once per day; group 3,
CPT-11 injected (50mg/kg) intraperitoneally once daily in the morning
with oral gavage of 0.25% (w/v) carboxymethylcellulose sodium salt
solution; group 4, CPT-11 injected (50 mg/kg) intraperitoneally once
daily in the morning and Inhibitor 5 gavaged (10 mg/d) twice per day
(every 10 hours). Total injected volume was identical for each ani-
mal. Mice were weighed and examined daily for signs of diarrhea
(fecal staining of skin, lose watery stool) and bloody diarrhea (black
sticky stool). Body weight, stool consistency, and blood in stool were
monitored daily using methods previously published (Cooper et al.,
1993; Wallace et al., 2010). Previous studies indicate that dosing at
∼60–80 mg/kg/day of CPT-11 for 4 days allows for observation of
delayed diarrhea around 15 days (Reagan-Shaw et al., 2008). A dos-
ing scheme of 50 mg/kg/day, once daily for 9 days, was chosen with
the intention of accelerating the onset of diarrhea while preventing
death. As outlined previously, 50 mg/kg CPT-11 in mice is roughly
equivalent to the 5 mg/kg typical human CPT- 11 dose based on
differences in body surface area (Brandi et al., 2006; Reagan-Shaw
et al., 2008). GI symptoms in group 3 started as early as day 2 and
up to day 10 and included decreased appetite, bowel movements,
mobility, and body weight. All animals were euthanized on day 11.
Results
In Vitro and Cell-Based E. coli b-Glucuronidase In-
hibition. Four compounds were chosen from high-throughput
screening results (Wallace et al., 2010; Ahmad et al., 2011) for
further functional and structural characterization (Fig. 1).
These compounds (Inhibitors 5–8) are relatively distinct in
structure from one another and are also distinct from the four
chemically similar compounds (Inhibitors 1–4) reported pre-
viously (Wallace et al., 2010). In in vitro assays with purified
E. coli b-glucuronidase, we found that all four compounds
functioned as inhibitors, with IC50 and Ki values ranging from
180 nM (Inhibitor 5) to 4 mM (Inhibitor 7) (Table 1), similar to
those observed previously with Inhibitors 1–4 (Wallace et al.,
2010). Only Inhibitors 5, 6, and 8, however, were effective against
the b-glucuronidase target in living E. coli cells. Inhibitor 7, the
weakest in vitro compound, showed no impact in cells, whereas
Inhibitors 5, 8, and 6 exhibited 300 nM, 1.2mM, and 7.3mMEC50
values, respectively (Table 1). The relatively potent in-cell
EC50 values compared with the in vitro IC50 values are likely
attributable to differences in compound entry, metabolism,
export, or partitioning within living cells; such features will
be examined in future studies. In summary, we have identified
novel compounds that exhibit in vitro and in-cell inhibition of
E. coli b-glucuronidase; this information expands our under-
standing of chemical moieties capable of disrupting bacte-
rial b-glucuronidase activity.
Selectivity for Bacterial b-Glucuronidase. We next
tested the ability of Inhibitors 5–8 to disrupt the activity of
b-glucuronidase from bovine liver, a mammalian enzyme
ortholog that processes larger glucosaminoglycan substrates
relative to the bacterial b-glucuronidases (Ray et al., 1999).
We found that Inhibitors 5–8 failed to impact the activity of
the bovine liver enzyme at concentrations up to 100 mM (Fig.
2), demonstrating that Inhibitors 5–8 are selective for the
E. coli b-glucuronidase. We also examined the in vitro effects of
these inhibitors on other glycosidase enzymes. We tested each
inhibitor against four commercially available enzymes: a plant
b-glucosidase (from the almond tree P. dulcis), a mollusk
b-mannosidase (from H. pomatia), and the b-galactosidases
from both E. coli and bovine sources. In all cases, Inhibitors
5–8 failed to exhibit inhibition at compound concentrations
up to 100 mM (unpublished data). Similarly, the previously
reported Inhibitors 1–4 also failed to exert an effect on these
glycosidases (unpublished data). Thus, we conclude that
the b-glucuronidases Inhibitors 1–8 are selective for the
bacterial b-glucuronidase and do not inhibit either mamma-
lian b-glucuronidase or members of the related family of sugar-
cleaving enzymes from a range of sources.
Lethality to Bacterial or Mammalian Cells. Eliminat-
ing toxic drug metabolites in the GI tract by disrupting
microbial b-glucuronidases requires that inhibitors are not
harmful to human or bacterial cells. Indeed, it is increasingly
well established that symbiotic microbiota are essential for GI
health (Human Microbiome Project Consortium, 2012). We
tested whether Inhibitors 5–8 were lethal to cultured E. coli
cells or HCT116 human colon cancer cells at compound
concentrations up to 100 mM.We found that all four inhibitors
did not affect the survival of either E. coli or HCT116 cells
(Fig. 3). Thus, they appear to satisfy the criteria that suc-
cessful compounds are relatively nontoxic to bacterial cells or
human epithelial cells.
Structure of E. coli b-Glucuronidase Complexed with
Inhibitor 8. To further our understanding of the molecular
basis of E. coli b-glucuronidase inhibition, we determined the
2.83 Å resolution crystal structure of the enzyme in complex
with Inhibitor 8 (PDB ID 4JHZ) (Table 2). The asymmetric
unit contained two b-glucuronidase monomers (Fig. 4A),
whereas C2 crystallographic symmetry produced the physio-
logically relevant b-glucuronidase tetramer (Wallace et al.,
2010). The apo (unliganded) structure ofE. coli b-glucuronidase
TABLE 2
Structure of E. coli b-glucuronidase complexed with Inhibitor 8
X-ray source APS ANL, SER-CAT, 22-ID
Space group C2





Unique reflections 31,648 (3115)
Multiplicity 4.1 (3.7)
Completeness (%) 98.82 (96.98)
I/s 10.09 (2.22)
Wilson B factor 59.72
Rwork 0.1964 (0.2653)
Rfree 0.2438 (0.3286)
Molecules per AU 2
No. of waters per AU 124
No. of protein residues per AU 1192
Average B-factor 70.80
RMS (bond lengths) 0.006
RMS (bond angles) 1.02
Ramachandran favored (%) 93
Ramachandran outliers (%) 0.42
APS ANL, Advanced Photon Source, Argonne National Laboratory; AU, asymmetric
unit; RMS, root mean square.
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was used as a molecular replacement searchmodel to eliminate
any previous ligand model bias. After careful refinement of
the protein model structure, electron density at 1.0 s level in
the composite omit map was present for Inhibitor 8 in both
monomers of the asymmetric unit (Fig. 4B). After refinement
of the atomic positions as well as their thermal displacement
parameters (B factors), the ligands had an occupancy of 0.93
and 0.91, with an average B-factor of 66.4 and 76.5 Å2 for
chain A and B, respectively.
Inhibitor 8 was placed in an orientation that both sat-
isfies the electron density and makes chemically reasonable
interactions with the neighboring amino acid side chains.
The compound binds to the entrance to the active site cleft of
E. coli b-glucuronidase (Fig. 4A), 3.5 Å from the catalytic re-
sidue Glu413 and contacts Asp163, Val446, Phe448, Tyr472,
andArg562 within the active site region of the enzyme (Fig.
5). Notably, in chain A it directly contacts Leu361 of the
bacterial loop, a region that is unique to the microbial forms of
theb-glucuronidase relative to themammalianb-glucuronidases
(Jain et al., 1996; Wallace et al., 2010). Inhibitor 8 binds in
a manner similar to Inhibitors 2 and 3 elucidated previously
in complexes with E. coli b-glucuronidase (Wallace et al.,
2010), occupying a similar location in the enzyme and
contacting five of the same residues (Fig. 5). Indeed, the
root mean square deviation between the Ca positions of the
Inhibitor 2- and Inhibitor 8-bound structures of E. coli
b-glucuronidase is 0.54 Å. However, although most residues
contacted by Inhibitor 8 are in the same position in the
Inhibitor 2 complex structure, the side chain of Leu361 shifts
by 3.6 Å. This observation suggests that the bacterial loop is
capable of conforming to the presence of different bound
inhibitors. Electron density in the simulated annealing omit
and 2Fo–Fc maps is less complete for Leu361 in chain B
compared with chain A.
The full bacterial loop of E. coli b-glucuronidase, residues
360–376, was visualized in the Inhibitor 2 and 3 cocrystal
structures (Wallace et al., 2010); in complex with Inhibitor 8,
although only residues 372–376 are ordered with average B
factors less than 80 Å2 (Fig. 6A). In the absence of a bound
ligand, the bacterial loop is not observed, as it gave no
interpretable electron density in the structure of apo E. coli
b-glucuronidase reported previously (Wallace et al., 2010).
Thus, we conclude that E. coli b-glucuronidase can be in-
hibited effectively by compounds, like Inhibitor 8, capable of
contacting only a portion of the loop unique to the microbial
b-glucuronidases. In support of this conclusion, we found that
a form of E. coli b-glucuronidase in which the bacterial loop
was deleted, D360–376, was not inhibited by up to 100 mM of
Inhibitors 5–8 (Fig. 6B). The D360–376 E. coli b-glucuronidase
exhibited comparable Km (260 mM for D360–376, 360 mM for
wild-type) values, but the Vmax (2.44 nmol/s for D360–376, 398
nmol/s for wild-type) and kcat (0.244 second
21 for D360–376,
39.8 second21 for wild-type) values were reduced by approxi-
mately two orders of magnitude. Thus, the bacterial loop is
essential for full activity of E. coli b-glucuronidase, as well as
its selective inhibition.
Fig. 4. (A) Crystal structure of the E. coli b-glucuronidase dimer in
complex with Inhibitor 8 (PDB ID 4JHZ). (B) Composite annealing omit
(sA weighted) 2.8 Å resolution electron density contoured at 1.0 s for
Inhibitor 8 in the active site of each monomer of E. coli b-glucuronidase.
Fig. 5. Contacts formed by Inhibitor 8 (pink) at the active site of E. coli
b-glucuronidase. Inhibitor 2 (yellow) from a previously resolved structure
is also shown, as are the side chains for the Inhibitor 8 and Inhibitor 2
complexes (blue and purple, respectively).
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Alleviation of CPT-11 Toxicity in Mice. Lastly, we
tested the ability of the most potent compound examined in
this study, Inhibitor 5 (Ki 5 180 nM, EC50 5 300 nM), to
alleviate CPT-11-induced intestinal toxicity in mice. We
divided BALB/cJ female mice into four groups of nine animals
each. Group 1 received an equivalent volume of only the vehi-
cle [0.25% (w/v) carboxymethylcellulose sodium salt solution]
intraperitoneally and by oral gavage twice per day. Group 2
received an oral gavage of Inhibitor 5 (10 mg/d) twice per day
starting on day21, aswell as an intraperitoneal injection of the
vehicle solution once per day. Group 3was injected withCPT-11
(50 mg/kg) intraperitoneal once per day and received an oral
gavage of the vehicle solution twice per day. Group 4 received
both an injection of CPT-11 (50mg/kg) once per day and an oral
gavage of Inhibitor 5 (10 mg/d) twice per day. The mice were
observed andweighed daily andwere examined for incidence of
diarrhea (Fig. 7). Groups 1 and 2 showed no evidence of toxicity
throughout the experiment. In group 3, GI symptoms were
observed as early as day 2, and incidences of bloody diarrhea
were observed in one-third of the mice at day 8 and in all
animals by day 10. In comparison, in group 4, in which themice
were pretreated with Inhibitor 5, no mice showed evidence of
bloody diarrhea by day 8 and less than 30% of mice showed
symptoms by day 10 (Fig. 7A).
The body weight of each mouse was also recorded each day
during the course of the experiment (Fig. 7B). Although
Inhibitor 5 alleviated most of the toxicity associated with the
CPT-11 treatment, it had no effect on the average body weight
of the mice. Moreover, group 2, which only received treatment
with Inhibitor 5, showed comparable body weights to the
vehicle-only group, but had significantly higher body weights,
starting at day 6, than group 4, which received treatment with
Inhibitor 5 in addition to CPT-11. These data indicate that the
presence of Inhibitor 5 significantly reduces the incidence of
acute GI toxicity caused by CPT-11, and they suggest that
Inhibitor 5 does not impact the systemic effects of this
anticancer drug, as measured by weight loss.
Discussion
Research endeavors such as the HumanMicrobiome Project
continue to expand our appreciation of the roles the symbiotic
microbiota play in mammalian physiology (Human Micro-
biome Project Consortium, 2012). It also appears that
widespread use of antibiotics may have subtle but serious
side effects on human health (Maurice et al., 2013). Addition-
ally, for patients with colorectal cancer, the use of antibiotics
to treat CPT-11-induced toxicity may lead to the increased
Fig. 6. (A) Bound Inhibitor 8 (pink) adjacent to the
largely disordered “bacterial loop” of E. coli b-glucu-
ronidase (blue). The completely ordered bacterial
loop of E. coli b-glucuronidase (purple) in complex
with Inhibitor 2 (yellow) is overlaid for comparison.
The image is in the same orientation as Fig. 5B. (B)
Inhibitors 5–8 at 100 mM inhibit wild-type (WT)
E. coli b-glucuronidase, but not a mutant E. coli
b-glucuronidase in which the bacterial loop (residues
360–376) have been deleted.
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prevalence of subdominant bacterial species with higher
overall b-glucuronidase activity in the GI tract and thus,
increased toxicity (Brandi et al., 2006). Studies have also
shown that the long-term use of neomycin in mice leads to
increased serum bilirubin that may interfere with proper
hepatic CPT-11 metabolism (Vítek et al., 2005). These
observations lead to the conclusion that the selective, non-
lethal inhibition of components of the GI microbiome will
be an important method of enhancing drug efficacy and
tolerance. In this report, we interrogate the roles bacterial
b-glucuronidases play in mammalian GI drug toxicity by
pharmacologically targeting this enzyme with potent and
selective inhibitors.
Each of the compounds described, Inhibitors 5–8, exhibited
strong in vitro inhibition of E. coli b-glucuronidase (Table 1)
but did not affect the viability of either cultured bacterial or
mammalian cells (Fig. 3). Only Inhibitor 7 failed to disrupt
b-glucuronidase activity in living E. coli cells. Furthermore,
because compounds were ineffective against mammalian
b-glucuronidase (Fig. 2) and a range of enzymes from the
glycosidase family, each inhibitor displayed selectivity toward
E. coli b-glucuronidase. The selectivity of our inhibitors is
particularly critical for their use in conjunction with CPT-11
because human b-glucuronidase expressed by tumor cells
appears to play an important role in the antitumor efficacy of
CPT-11 through the reactivation of SN-38G to SN-38 in the
tumor microenvironment (Tobin et al., 2006; Huang et al.,
2011). Of the four compounds described here, only Inhibitor 5
(Ki and IC50 values of 180 and 540 nM, respectively) displayed
potency comparable with our previously-characterized inhib-
itors, which have a scaffold not shared by the four inhibitors
outlined in this study (Wallace et al., 2010). As such, these
data advance our understanding of the chemical moieties
capable of selective bacterial b-glucuronidase inhibition.
We successfully determined the X-ray crystal structure of
one of our inhibitors (Inhibitor 8) in complex with E. coli
b-glucuronidase (Fig. 4). This adds to our knowledge of E. coli
b-glucuronidase inhibition that started with the structures of
the complexes of Inhibitors 2 and 3 reported previously
(Wallace et al., 2010). Similar to those structures, Inhibitor 8
binds at the entrance to the active site cleft and forms related
contacts, including one with the catalytic glutamic acid
residue, Glu413. Importantly, Inhibitor 8 also makes a hydro-
phobic contact with Leu361, which is part of the bacterial loop
Fig. 7. (A) Groups of nine BALB/cJ mice were dose with
either vehicle, Inhibitor 5, CPT-11, or pretreated with
Inhibitor 5 followed by CPT-11 and then examined for
incidences of CPT-11–induced toxicity (i.e., bloody di-
arrhea). (B) The mice were weighed daily. Administra-
tion of CPT-11 incited the loss of body weight during
treatment. Oral administration of Inhibitor 5 had no
protective effects on body weight during CPT-11 treat-
ment. Inhibitor 5 only and CPT-11 + Inhibitor 5 groups
were analyzed for statistical significance. **P , 0.01;
***P , 0.001.
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unique to the microbial enzymes. Overlaying the structures of
the complexes with Inhibitor 2 and Inhibitor 8, it is apparent
that Leu361 has shifted to facilitate binding, suggesting that
bacterial loop flexibility is involved in inhibition (Fig. 6). The
observation that the bacterial loop in the Inhibitor 8 complex
structure is disordered for the eight residues C-terminal to
Leu361 supports that conclusion. Mutagenesis studies in
which the bacterial loop has been deleted confirm its im-
portance in microbial b-glucuronidase inhibition (Fig. 6).
Lastly, only the previously reported Inhibitor 1 had been
examined to date in drug-induced GI toxicity studies in mice
(Wallace et al., 2010; LoGuidice et al., 2012). In this report, we
tested the in vivo efficacy of our most effective compound
outlined here, Inhibitor 5, in amousemodel of CPT-11 toxicity
(Fig. 7). Groups of BALB/cJ mice were dosed with Inhibitor 5,
CPT-11, or a combination of both. The group that received
CPT-11 alone developed bloody diarrhea by day 8, and 100%
of the mice showed signs of this toxicity by day 10. The group
that was treated with Inhibitor 5 orally, along with CPT-11
intraperitoneally, had significantly fewer incidents of bloody
diarrhea compared with the CPT-11 group, highlighting the
protective effects of Inhibitor 5. It is also interesting to note
that the mice that received CPT-11 lost body weight at the
same rate regardless of treatment with Inhibitor 5. This
suggests that Inhibitor 5 protected against CPT-11–induced
GI toxicity but that the systemic pharmacodynamics of CPT-11
in the mouse are not impacted. A more comprehensive exami-
nation of tumor xenografts and pharmacokinetics will be
required to substantiate this conclusion.
We have described the inhibitory profile of a range of
chemically distinct compounds and assessed their potential
as orally delivered pharmacological agents. They are in
vitro inhibitors to E. coli b-glucuronidase and, with the
exception of Inhibitor 7, are also effective in E. coli cells.
Moreover, our inhibitors appear to be selective for bacterial
b-glucuronidase and nonlethal to bacterial and mammalian
cells. The structural data presented here, along with the
data from our previously characterized inhibitors, will allow
us to better understand their mechanism of selective mi-
crobial b-glucuronidase inhibition. As such, they may facili-
tate the development of therapeutics capable of alleviating
drug-induced GI toxicity generated by symbiotic microbial
b-glucuronidases.
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